Prevalence of Latent Tuberculosis in High Risk Young Children Attending Pediatric Hospital of Assiut University
Condition:   Latent Tuberculosis Intervention:   Drug: Tuberculin, Purified Protein 5Unt/0.1 mL Solution Sponsor:   Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2019 Category: Research Source Type: clinical trials

Prevalence of Latent Tuberculosis in High Risk Young Children
Condition:   Latent Tuberculosis Intervention:   Drug: Tuberculin, Purified Protein 5Unt/0.1 mL Solution Sponsor:   Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2019 Category: Research Source Type: clinical trials

Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis(SCRIPT-TB)
Condition:   Silicosis Tuberculosis Intervention:   Drug: Isoniazid´╝ŤRifapentine Sponsors:   Huashan Hospital;   Wenling No.1 People's Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2019 Category: Research Source Type: clinical trials

Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Conditions:   Renal Impairment;   Tuberculosis Intervention:   Drug: PA 824 Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Conditions:   Tuberculosis, Multidrug-Resistant;   Tuberculosis;   Tuberculosis, Pulmonary;   Mycobacterium Infections;   Bacterial Infections;   Gram-Positive Bacterial Infections Interventions:   Drug: Bedaquiline;   Drug: Delamanid;   Drug: Clofazimine;   Drug: Linezolid;   Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines Sponsors:   Médecins Sans Frontières, France;   Partners in Health;   Harvard Medical School;   Epic...
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Conditions:   Renal Impairment;   Tuberculosis Intervention:   Drug: PA 824 Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Conditions:   Tuberculosis, Multidrug-Resistant;   Tuberculosis;   Tuberculosis, Pulmonary;   Mycobacterium Infections;   Bacterial Infections;   Gram-Positive Bacterial Infections Interventions:   Drug: Bedaquiline 100 MG;   Drug: Delamanid 50 MG Oral Tablet;   Drug: Clofazimine Pill;   Drug: Linezolid Pill;   Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines Sponsors:   Médecins Sans Frontières, France;   Partner...
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Conditions:   Renal Impairment;   Tuberculosis Intervention:   Drug: PA 824 Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Conditions:   Tuberculosis, Multidrug-Resistant;   Tuberculosis;   Tuberculosis, Pulmonary;   Mycobacterium Infections;   Bacterial Infections;   Gram-Positive Bacterial Infections Interventions:   Drug: Bedaquiline 100 MG;   Drug: Delamanid 50 MG Oral Tablet;   Drug: Clofazimine Pill;   Drug: Linezolid Pill;   Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines Sponsors:   Médecins Sans Frontières, France;   Partner...
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Conditions:   Renal Impairment;   Tuberculosis Intervention:   Drug: PA 824 Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Conditions:   Tuberculosis, Multidrug-Resistant;   Tuberculosis;   Tuberculosis, Pulmonary;   Mycobacterium Infections;   Bacterial Infections;   Gram-Positive Bacterial Infections Interventions:   Drug: Bedaquiline 100 MG;   Drug: Delamanid 50 MG Oral Tablet;   Drug: Clofazimine Pill;   Drug: Linezolid Pill;   Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines Sponsors:   Médecins Sans Frontières, France;   Partner...
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Conditions:   Renal Impairment;   Tuberculosis Intervention:   Drug: PA 824 Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Conditions:   Tuberculosis, Multidrug-Resistant;   Tuberculosis;   Tuberculosis, Pulmonary;   Mycobacterium Infections;   Bacterial Infections;   Gram-Positive Bacterial Infections Interventions:   Drug: Bedaquiline 100 MG;   Drug: Delamanid 50 MG Oral Tablet;   Drug: Clofazimine Pill;   Drug: Linezolid Pill;   Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines Sponsors:   Médecins Sans Frontières, France;   Partner...
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Conditions:   Renal Impairment;   Tuberculosis Intervention:   Drug: PA 824 Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Conditions:   Tuberculosis, Multidrug-Resistant;   Tuberculosis;   Tuberculosis, Pulmonary;   Mycobacterium Infections;   Bacterial Infections;   Gram-Positive Bacterial Infections Interventions:   Drug: Bedaquiline 100 MG;   Drug: Delamanid 50 MG Oral Tablet;   Drug: Clofazimine Pill;   Drug: Linezolid Pill;   Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines Sponsors:   Médecins Sans Frontières, France;   Partner...
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Conditions:   Renal Impairment;   Tuberculosis Intervention:   Drug: PA 824 Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Conditions:   Tuberculosis, Multidrug-Resistant;   Tuberculosis;   Tuberculosis, Pulmonary;   Mycobacterium Infections;   Bacterial Infections;   Gram-Positive Bacterial Infections Interventions:   Drug: Bedaquiline 100 MG;   Drug: Delamanid 50 MG Oral Tablet;   Drug: Clofazimine Pill;   Drug: Linezolid Pill;   Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines Sponsors:   Médecins Sans Frontières, France;   Partner...
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Conditions:   Renal Impairment;   Tuberculosis Intervention:   Drug: PA 824 Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Conditions:   Tuberculosis, Multidrug-Resistant;   Tuberculosis;   Tuberculosis, Pulmonary;   Mycobacterium Infections;   Bacterial Infections;   Gram-Positive Bacterial Infections Interventions:   Drug: Bedaquiline 100 MG;   Drug: Delamanid 50 MG Oral Tablet;   Drug: Clofazimine Pill;   Drug: Linezolid Pill;   Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines Sponsors:   Médecins Sans Frontières, France;   Partner...
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Conditions:   Renal Impairment;   Tuberculosis Intervention:   Drug: PA 824 Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Conditions:   Tuberculosis, Multidrug-Resistant;   Tuberculosis;   Tuberculosis, Pulmonary;   Mycobacterium Infections;   Bacterial Infections;   Gram-Positive Bacterial Infections Interventions:   Drug: Bedaquiline 100 MG;   Drug: Delamanid 50 MG Oral Tablet;   Drug: Clofazimine Pill;   Drug: Linezolid Pill;   Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines Sponsors:   Médecins Sans Frontières, France;   Partner...
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Conditions:   Renal Impairment;   Tuberculosis Intervention:   Drug: PA-824 Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Conditions:   Tuberculosis, Multidrug-Resistant;   Tuberculosis;   Tuberculosis, Pulmonary;   Mycobacterium Infections;   Bacterial Infections;   Gram-Positive Bacterial Infections Interventions:   Drug: Bedaquiline 100 MG;   Drug: Delamanid 50 MG Oral Tablet;   Drug: Clofazimine Pill;   Drug: Linezolid Pill;   Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines Sponsors:   Médecins Sans Frontières, France;   Partner...
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials

Non-inferiority of Portable Versus Desktop Spirometry
Conditions:   Asthma;   COPD Interventions:   Device: AioCare;   Device: Spirometer USB CPFS/D (MGC Diagnostics) Sponsors:   National Institute for Tuberculosis and Lung Diseases, Poland;   HealthUp Sp. z o.o. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2019 Category: Research Source Type: clinical trials